Vanslembrouck, R.

liver lanreotide patient volume liver volume polycystic month treatment kidney 12 months disease polycystic liver disease study kidney volume change 6 months polycystic kidney disease adpkd placebo trial radboud university nijmegen effect polycystic liver baseline somatostatin lanreotide treatment somatostatin analogues group result university nijmegen table department hepatology analogue signi adpkd patients autosomal gastroenterology symptom aliment pharmacol octreotide hepatic figure increase health ficant polycystic liver volume signi ficant change university hospital leuven lanreotide 120 mg point radboud polycystic kidneys placebo group keimpema growth serum outcome level bene ficial effect follow-up liver cysts drenth times uln quality pharmacol aliment difference therapy hepatic cystogenesis biliary signi ficant hospital perception tract centre hepatic cysts advance health perception